<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neoadjuvant fluorouracil, epirubicin, cyclophosphamide (FEC) followed by docetaxel, trastuzumab, and pertuzumab (THP) for HER2-positive* breast cancer&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neoadjuvant fluorouracil, epirubicin, cyclophosphamide (FEC) followed by docetaxel, trastuzumab, and pertuzumab (THP) for HER2-positive* breast cancer<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Neoadjuvant fluorouracil, epirubicin, cyclophosphamide (FEC) followed by docetaxel, trastuzumab, and pertuzumab (THP) for HER2-positive* breast cancer<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"> <p><strong>Cycle length:</strong> Every 21 days (for both neoadjuvant and adjuvant components).</p> <strong>Duration of therapy:</strong> Prior to surgery, administer three cycles of FEC followed by three cycles of DHP.<sup>¶</sup> Following surgery, adjuvant treatment consists of trastuzumab alone to complete one year of therapy.</td> </tr> <tr class="divider_bottom"> <td class="subtitle1">Drug</td> <td class="subtitle1">Dose and route</td> <td class="subtitle1">Administration</td> <td class="subtitle1">Given on days</td> </tr> <tr> <td colspan="4"><strong>Before surgery (neoadjuvant treatment)</strong></td> </tr> <tr> <td>Fluorouracil (FU)</td> <td>500 mg/m<sup>2</sup> IV</td> <td>Administer undiluted (50 mg/mL) as an IV push bolus over five minutes.</td> <td>Cycles 1 to 3: Day 1</td> </tr> <tr> <td>Epirubicin</td> <td>100 mg/m<sup>2</sup> IV</td> <td>Administer into a free-flowing IV infusion of NS<sup>◊</sup> over 3 to 20 minutes.</td> <td>Cycles 1 to 3: Day 1</td> </tr> <tr> <td>Cyclophosphamide</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 to 500 mL NS or D5W<sup>◊</sup> and administer over 30 to 60 minutes.</td> <td>Cycles 1 to 3: Day 1</td> </tr> <tr> <td>Pertuzumab (loading dose)<sup>Δ</sup></td> <td>840 mg IV</td> <td>Dilute in 250 mL NS<sup>◊</sup> and administer over 60 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycle 4: Day 1</td> </tr> <tr> <td>Pertuzumab<sup>Δ</sup></td> <td>420 mg IV</td> <td>Dilute in 250 mL NS<sup>◊</sup> and administer over 30 to 60 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycles 5 to 6: Day 1</td> </tr> <tr> <td>Trastuzumab (loading dose)<sup>Δ</sup></td> <td>8 mg/kg IV</td> <td>Dilute in 250 mL NS<sup>◊</sup> and administer over 90 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycle 4: Day 1</td> </tr> <tr> <td>Trastuzumab<sup>Δ</sup></td> <td>6 mg/kg IV</td> <td>Dilute in 250 mL NS<sup>◊</sup> and administer over 30 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycles 5 to 6: Day 1</td> </tr> <tr> <td>Docetaxel<sup>§</sup></td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS<sup>◊</sup> to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Cycles 4 to 6: Day 1</td> </tr> <tr> <td colspan="4"><strong>After surgery (adjuvant treatment)</strong></td> </tr> <tr> <td>Trastuzumab (loading dose)<sup>Δ</sup></td> <td>8 mg/kg IV</td> <td>Dilute in 250 mL NS<sup>◊</sup> and administer over 90 minutes. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycle 7: Day 1</td> </tr> <tr class="divider_bottom"> <td>Trastuzumab<sup>Δ</sup></td> <td>6 mg/kg IV</td> <td>Dilute in 250 mL NS<sup>◊</sup> and administer over 30 minutes for subsequent doses. <strong>DO NOT</strong> mix with D5W and <strong>DO NOT</strong> infuse as an IV push or bolus.</td> <td>Cycle 8 and then to complete one year of therapy or a maximum of 15 total cycles: Day 1</td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Hydration</strong></td> <td colspan="3"> <ul> <li>Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis.<sup>[2]</sup></li> <li>Refer to UpToDate topics on hemorrhagic cystitis in cancer patients.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>HIGH (&gt;90% risk of emesis) during treatment with FEC (cycles 1 to 3).</li> <li>LOW (10 to 30% risk of emesis) during the treatment with DHP (cycles 4 to 6).</li> <li>MINIMAL (&lt;10% risk of emesis) during monotherapy with trastuzumab (cycle 7 until completion of treatment).</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration.<sup>[3]</sup> Premedication is not routinely indicated for pertuzumab or during FEC. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or an NSAID if flu-like symptoms develop within 24 hours of drug administration.</li> <li>Refer to UpToDate topics on infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy and infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Epirubicin is a vesicant; avoid extravasation. Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Primary prophylaxis with G-CSF is not indicated. The rate of febrile neutropenia associated with FEC is approximately 10%.<sup>[4,5]</sup> In the NEOSPHERE trial, the incidence of neutropenic fever during treatment with docetaxel with trastuzumab and pertuzumab was 9%.<sup>[6]</sup></li> <li>Refer to UpToDate topics on prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>Dose modification of FU may be needed for patients with hepatic impairment.<sup>[7]</sup> A lower starting dose of cyclophosphamide and epirubicin may be needed for patients with renal or hepatic impairment.<sup>[2,8]</sup> Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &gt;1.5 times the ULN.<sup>[3]</sup></li> <li>Refer to UpToDate topics on chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiac issues</strong></td> <td colspan="3"> <ul> <li>Epirubicin, trastuzumab, and pertuzumab are associated with cardiotoxicity; assess baseline LVEF prior to therapy. Patients with a baseline LVEF &lt;55% were excluded from the study.<sup>[1]</sup></li> <li>Refer to UpToDate topics on cardiotoxicity of trastuzumab and other HER2-targeted agents, clinical manifestations, monitoring, and diagnosis of anthracycline-induced cardiotoxicity, and prevention and management of anthracycline cardiotoxicity.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Pulmonary issues</strong></td> <td colspan="3"> <ul> <li>Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease.</li> <li>Refer to UpToDate topics on pulmonary toxicity associated with antineoplastic therapy, molecularly targeted agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan="3"> <ul> <li>Caution is required if administering docetaxel with strong CYP3A4 inhibitors.<sup>¥</sup> According to the United States Prescribing Information, avoid the use of docetaxel with strong CYP3A4 inhibitors (if possible). If concomitant therapy cannot be avoided, monitor closely for toxicity and consider a docetaxel dose reduction.<sup>[3]</sup> Docetaxel dose reductions for concomitant therapies should be individualized based on patient factors (eg, performance status) and the intent of therapy (ie, curative or palliative).</li> <li>Refer to "Suggested dose modifications for toxicity" below.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential and platelet count every three weeks prior to each cycle during neoadjuvant chemotherapy (cycles 1 to 6). They need not be checked during adjuvant trastuzumab.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Serum electrolytes and liver and renal function tests every three weeks prior to each cycle of neoadjuvant chemotherapy (cycles 1 to 6). These labs need not be checked during adjuvant trastuzumab.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias) during FEC.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess changes in neurologic function prior to each cycle of docetaxel.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>It is recommended to observe the patient for one hour after the initial dose of pertuzumab and for 30 minutes after all subsequent doses for signs of infusion reactions.<sup>[9]</sup></li> <li>Refer to UpToDate topics on infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>In the clinical trial, LVEF was assessed every second cycle<sup>[1]</sup>, but there are no standard guidelines for cardiac monitoring in routine clinical practice. A reasonable strategy is to assess cardiac function prior to initiation of both neoadjuvant FEC (pre-cycle 1), neoadjuvant DHP (pre-cycle 4), and adjuvant trastuzumab monotherapy (pre-cycle 7). During adjuvant trastuzumab, consider repeating evaluation every 12 weeks (prior to cycles 12 and 16) and if clinically indicated.</li> <li>Refer to UpToDate topics on clinical manifestations, monitoring, and diagnosis of anthracycline-induced cardiotoxicity, prevention and management of anthracycline cardiotoxicity, and cardiotoxicity of trastuzumab and other HER2-targeted agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li><strong>During the neoadjuvant portion of therapy with FEC:</strong> The published report did not include specific recommendations for dose modification during FEC or DHP.<sup>[1]</sup> Based on the original FEC trial in metastatic breast cancer, if the ANC is &lt;1500/microL or platelets are &lt;100,000/microL on day 1 of each cycle, therapy should be delayed until counts recover.<sup>[4]</sup> Reduce epirubicin by 10 mg/m<sup>2</sup> for subsequent cycles in patients who develop severe prolonged neutropenia (&lt;500/microL lasting seven days or more), severe thrombocytopenia (platelet count &lt;50,000/microL), or febrile neutropenia.<sup>[1,4]</sup></li> <li><strong>During the neoadjuvant portion of therapy with docetaxel:</strong> Docetaxel should only be administered if the ANC is &gt;1500/microL. For patients who develop severe prolonged neutropenia (&lt;500/microL lasting seven days or more), febrile neutropenia, or a grade 4 infection (ie, an infection with life-threatening consequences) at the docetaxel dose of 75 mg/m<sup>2</sup>, reduce subsequent doses to 60 mg/m<sup>2</sup>.<sup>[3]</sup> For patients who developed severe symptoms at a docetaxel dose of 100 mg/m<sup>2</sup>, reduce dose to 75 mg/m<sup>2</sup>. If symptoms recur, a second dose reduction to 60 mg/m<sup>2</sup> was performed in the protocol.<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Hepatotoxicity</strong></td> <td colspan="3"> <ul> <li>Docetaxel dose reduction (as outlined above) may also be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy.<sup>[3]</sup></li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiotoxicity</strong></td> <td colspan="3"> <ul> <li>During neoadjuvant FEC treatment, if cardiac symptoms develop or the LVEF falls to ≥10% below the lower limit of normal or there is a ≥15% drop below the patient's baseline, discontinue epirubicin.<sup>[4]</sup> Hold both trastuzumab and pertuzumab during the neoadjuvant portion of this protocol if the LVEF drops to &lt;50% with a 10% or greater absolute decrease below baseline. Guidelines for managing cardiac dysfunction during therapy with HER2-targeted agents are available.<sup>[1]</sup></li> <li>Refer to UpToDate topics on cardiotoxicity of trastuzumab and other HER2-targeted agents.</li> <li>Cardiotoxicity observed with FU includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. There is no recommended dose for resumption of FU administration following development of cardiac toxicity, and the drug should be discontinued.<sup>[7]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Pulmonary toxicity</strong></td> <td colspan="3"> <ul> <li>Discontinue trastuzumab for serious pulmonary toxicity.</li> <li>Refer to UpToDate topics on pulmonary toxicity associated with antineoplastic therapy, molecularly targeted agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cutaneous, mucosal, and neurologic toxicity</strong></td> <td colspan="3"> <ul> <li>During FEC, hold FU for ≥grade 2 palmar-plantar erythrodysesthesia and reduce subsequent dose by 20%.<sup>[7]</sup> During docetaxel, for severe or cumulative cutaneous reactions (erythema and desquamation), grade 2 or worse mucositis, grade 3 or 4 stomatitis, or moderate neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m<sup>2</sup>.<sup>[3]</sup> Discontinue if toxicity persists.</li> <li>Refer to UpToDate topics on cutaneous side effects of conventional chemotherapy agents.</li> <li>There is no recommended dose for resumption of FU administration following development of hyperammonemic encephalopathy, acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances; the drug should be permanently discontinued.<sup>[7]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Gastrointestinal toxicity</strong></td> <td colspan="3"> <ul> <li>During FEC (cycles 1 to 3), hold FU for grade 2 or worse diarrhea or mucositis and restart at a 20% lower dose after complete resolution. For the first episode of grade 3 to 4 diarrhea or grade 3 to 4 mucositis, reduce FU by 20%; subsequent episodes, reduce both FU and epirubicin by 20%<sup>[4-6]</sup> or discontinue treatment. During docetaxel (cycles 3 to 6), delay docetaxel for grade 2 or worse diarrhea and restart at a 20% lower dose after complete resolution; reduce docetaxel by 20% for the first episode of grade 3 diarrhea.</li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for DPD deficiency.</li> <li>Refer to UpToDate topics on enterotoxicity of chemotherapeutic agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Infusion reactions</strong></td> <td colspan="3"> <ul> <li>Respond as clinically indicated with supportive care and possible discontinuation of therapy for severe reactions.</li> <li>Refer to UpToDate topics on infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy.</li> </ul> </td> </tr> <tr> <td class="subtitle1_left" colspan="4"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes"><p>HER2: human epidermal growth factor receptor 2; IV: intravenous; NS: normal saline; D5W: 5% dextrose in water; NSAID: nonsteroidal anti-inflammatory drug; G-CSF: granulocyte-colony stimulating factors; ULN: upper limit of normal; LVEF: left ventricular ejection fraction; CYP3A4: cytochrome P450 3A4; CBC: complete blood count; ANC: absolute neutrophil count; DPD: dihydropyrimidine dehydrogenase; IHC: immunohistochemical staining; FISH: fluorescence in situ hybridization.</p>
<p>* High levels of HER2 overexpression, as determined by either 3+ IHC or positive FISH, are used to select patients for therapy with trastuzumab and pertuzumab. Refer to UpToDate topic on "HER2 and predicting response to therapy in breast cancer".</p>
<p>¶ During cycles 3 to 6, administer pertuzumab, trastuzumab, and docetaxel sequentially, with either pertuzumab (followed by a 30- to 60-minute observation period) or trastuzumab administered first; administer docetaxel after both pertuzumab and trastuzumab.<sup>[9]</sup></p>
<p>Δ A repeat loading dose of trastuzumab is required if scheduled treatment has been delayed for over one week, which is the case for patients resuming trastuzumab after definitive surgery. If adverse reactions occur for which discontinuation of trastuzumab or pertuzumab is indicated, both drugs should be discontinued. Dose modifications of trastuzumab and pertuzumab were not allowed in the original protocol.<sup>[1]</sup></p>
<p>◊ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</p>
<p>§ If tolerated during cycle 4, the dose of docetaxel was increased to 100 mg/m<sup>2</sup> for cycles 5 and 6 in the protocol.<sup>[1]</sup></p>
¥ A list of strong and moderate CYP3A4 inhibitors is available as a separate table in UpToDate. Specific interactions may be determined by use of the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program included within UpToDate.</div><div class="graphic_reference">References:
<ol>
<li>Schneeweiss A, et al. Ann Oncol 2013; 24:2278.</li>
<li>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 14, 2018).</li>
<li>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on March 15, 2022).</li>
<li>Brufman G, et al. Ann Oncol 1997; 8:155.</li>
<li>Wildiers H, et al. Breast Cancer Res Treat 2009; 114:103.</li>
<li>Gianni L, et al. Lancet Oncol 2012; 13:25.</li>
<li>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 14, 2018).</li>
<li>Epirubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 14, 2018).</li>
<li>Pertuzumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 14, 2018).</li>
</ol></div><div id="graphicVersion">Graphic 96464 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
